Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12615001048572
Ethics application status
Approved
Date submitted
2/09/2015
Date registered
7/10/2015
Date last updated
7/10/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsy
Query!
Scientific title
Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsy
Query!
Secondary ID [1]
287393
0
none
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
cerebral palsy
296099
0
Query!
osteoporosis
296100
0
Query!
Condition category
Condition code
Musculoskeletal
296354
296354
0
0
Query!
Osteoporosis
Query!
Neurological
296355
296355
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
4mg zoledronic acid (intravenous) to be given as a once off infusion
Calcium supplementation: 1000mg daily orally/via PEG
Vitamin D supplementation: 2000 international units daily orally/via PEG
Calcium and vitamin D supplementation will commence prior to infusion to ensure adequate levels and reduction of side effects
Laboratory testing will be performed to determine if vitamin D supplementation is adequate
Query!
Intervention code [1]
292746
0
Treatment: Drugs
Query!
Comparator / control treatment
No placebo infusion will be given
Calcium supplementation: 1000mg daily
Vitamin D supplementation: 2000 international units daily
Laboratory testing will be performed to determine if vitamin D supplementation is adequate
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
296004
0
changes in bone mineral density as measured by dual energy xray absorptiometry (DXA)
Query!
Assessment method [1]
296004
0
Query!
Timepoint [1]
296004
0
12 and 24 months
Query!
Secondary outcome [1]
317210
0
changes in bone density as measured by high resolution peripheral quantitative computed tomography (HR-pQCT)
Query!
Assessment method [1]
317210
0
Query!
Timepoint [1]
317210
0
12 and 24 months
Query!
Secondary outcome [2]
317211
0
Changes in bone turnover markers (serum ALP, CTX, P1NP -all assessed through blood samples)
Query!
Assessment method [2]
317211
0
Query!
Timepoint [2]
317211
0
12 and 24 months
Query!
Eligibility
Key inclusion criteria
aged greater or equal to 18 years
cerebral palsy
non ambulatory (includes those who can stand for transfers only).
Z score at lumbar spine or proximal femur less or equal to -2.0
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Secondary cause for bone disease (hypoparathyroidism, hyperparathyroidism, hypothyroidism, hyperthyroidism, rheumatoid arthritis, Paget’s disease
- Hypocalcaemia/hypercalcaemia
- Previous use of bisphosphonates in the last 2 years
- Current use of medication to treat osteoporosis: strontium, denosumab
- Use of glucocorticoids (washout period of 1 year)
- Calculated creatinine clearance of <30ml/min as per Cockcroft Gault equation
- Pregnancy (F)
- Post-menopausal (F)
- Current use of medications that can increase risk of renal dysfunction: diuretics, aminoglycosides
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/02/2016
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment postcode(s) [1]
10231
0
3168 - Clayton
Query!
Funding & Sponsors
Funding source category [1]
291961
0
Self funded/Unfunded
Query!
Name [1]
291961
0
Query!
Address [1]
291961
0
Query!
Country [1]
291961
0
Query!
Primary sponsor type
Individual
Query!
Name
Anne Trinh
Query!
Address
Hudson Institute of Medical Research
27-31 Wright St Clayton VIC 3168
Query!
Country
Australia
Query!
Secondary sponsor category [1]
290626
0
None
Query!
Name [1]
290626
0
Query!
Address [1]
290626
0
Query!
Country [1]
290626
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
293456
0
Monash HREC
Query!
Ethics committee address [1]
293456
0
Research Support Services Level 2, I Block Monash Health 246 Clayton Rd, Clayton VIC 3168
Query!
Ethics committee country [1]
293456
0
Australia
Query!
Date submitted for ethics approval [1]
293456
0
Query!
Approval date [1]
293456
0
13/08/2015
Query!
Ethics approval number [1]
293456
0
15353A
Query!
Summary
Brief summary
Broken bones and thin bones are common in people with cerebral palsy. This is due to a number of factors including reduced activity and standing, poor nutrition, use of medications for epilepsy and reduced sex hormones. Thin bones are becoming more of a problem as adults with cerebral palsy are getting older. In older women and men with thin bones, there are good drug treatments available to reduce their risk of breaking a bone. One such treatment is zoledronic acid, which is given as an intravenous infusion once a year. This drug is currently being used and registered in Australia for treatment of osteoporosis (thin bones) in older women and men. The aim of this study is to see if zoledronic acid can be used in adults with cerebral palsy to improve their bone strength and reduce their risk of breaking bones. This drug has not be used in a study of adults with cerebral palsy before.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
60006
0
Dr Anne Trinh
Query!
Address
60006
0
Hudson Institute of Medical Research
27-31 Wright St Clayton, VIC, 3168
Query!
Country
60006
0
Australia
Query!
Phone
60006
0
+61395946666
Query!
Fax
60006
0
Query!
Email
60006
0
[email protected]
Query!
Contact person for public queries
Name
60007
0
Anne Trinh
Query!
Address
60007
0
Hudson Institute of Medical Research
27-31 Wright St Clayton, VIC, 3168
Query!
Country
60007
0
Australia
Query!
Phone
60007
0
+61395946666
Query!
Fax
60007
0
Query!
Email
60007
0
[email protected]
Query!
Contact person for scientific queries
Name
60008
0
Anne Trinh
Query!
Address
60008
0
Hudson Institute of Medical Research
27-31 Wright St Clayton, VIC, 3168
Query!
Country
60008
0
Australia
Query!
Phone
60008
0
+61395946666
Query!
Fax
60008
0
Query!
Email
60008
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF